World's Best-Selling Drug Prediction sits in 2025: The wind is back

TextsThe list of TOP10 sales of iron drugs, like the Wu-Man Jianghu Huashan sword, the Nobel Prize in the scientific research field, the Oscar stake in the film and television circle, full of swords and lightsabershadows, fierce competition under which only the ableBased on the 2025 World's Best-Selling Drug Forecast report, published by GlobalData, a leading global data analytics company, this article describes the competitive landscape of drug targets, pathion sydds and ChinaTable 1The 2025 drug predicts a breakthrough in clinical efficacy of THE global TOP10PD-1 inhibitor: once it works, patients can survive for a long time and hope to cure the tumorSince its inception, the clinical indications of PD-1 inhibitors have attracted much attention, the market is hotly anticipated fighting is a topic of relishOn October 29, 2019, Mersadon reported third-quarter sales of $7.973 billion in the first three quarters of 2019, with full-year sales expected to exceed $11 billionO-drugs, on the other hand, pale in comparison: O drug sales in the first three quarters of 2019 were $5.441 billion, and the U.Smarket posted negative growthThe former time, do the king, empty string broken what to ask for? Once led the trend of O medicine to watch the K drug destroyed and decadent growth, estimated to be also smugAccording to the data released before the Mersadong website, 60-65% of the global sales of K drug comes from lung cancer, and NSCLC, as a must-have place in the field of cancer, determines the success or failure of PD-(L) 1 monotonicaK drug in the NSCLC single-drug first-line drug or combined chemotherapy first-line drug use has formed an uncontrollable advantage: and correspondingly, O drug in CheckMate-026 and CheckMate-227P2 fold sand, missed the NSCLC first-line opportunityThe only good thing is that at the 2019 ESMO meeting, the O-drug-Ipimo synmotic phase III clinical success was significantly successful, both pD-L1 positive and negativeBMS scoured biomarkers PD-L1 and TMB around and finally found the right clinical solutionO drug after several years of wind and rain, NSCLC market has long been human non-: Roche's T drug and AstraZeneca's I drug has long been a blind eye, has been approved first-line NSCLC scale cancer and non-surgical Phase III NSCLC-assisted treatmentFrom the perspective of approved indications, as of November 2019, K drug has been approved for a total of 15 tumor strains, 21 indications, force pressure O drug has become the most widely used PD-1 inhibitorO drug since August 2018 after taking the SCLC third line basically numerous particles, in many indications have failed: SCLC second line, liver cancer first line .. Table 2 K drug approved indications domestic PD-(L) 1 mono-resistance market, Baiji Shenzhou's Terelli Zhu monosarin is about to become the sixth domestic, the world's 10th listed PD-(L) 1 monotonica, Hodgkin lymphoma ended the approval stage, urinary skin cancer in the NDA stage According to market insiders, the domestic PD-(L) 1 monotag is expected to be around 7-8 billion, Hengrui and Mersadong about 2 billion yuan, the other three about 1 billion K drug by virtue of the first-line NSCLC indications approved, the market rapid lys, the opposite O drug in the domestic PD-1 single resistance under the impact, it seems that some successor powerless Recently, the domestic PD-1 single anti-health insurance catalog negotiations are also in full swing, the small news is divided, the domestic O drug is basically nailed, mainly whether K drug is willing to reduce prices there is a controversy The approval of clinical indications, the competition of the medical insurance catalogue, the game of capital.. All make the domestic PD-1 inhibitor market battle unresolved and full of expectations Table 3 China's approved PD-(L) 1 monotogenalist condition was once geometric, the cardiovascular market was born atovastatin and clopidogrel and other legendary drugs, leading the market, and now, with the expiration of patents, some lonely As today's cardiovascular-worthy leader - Apixaban, with excellent performance in the clotting market, 2025 sales are expected to take $18.7 billion, and again the glory of the past Among the globally listed oral anticoagulants, the market share of clopidogrel has continued to decline since 2014, with chagulation factor Xa inhibitors represented by the saban class becoming dominant, representing the drugs of apixaban eandre Although apixaban was late in the market, it was clinically favored by the physician community with better safety performance, and in 2017, apixaban overtook Delavaban to become the world's best-selling anticoagulant drug, and has since maintained a growth rate of 33%, constantly pulling away from the successors In the domestic market, due to lack of channel advantages and late listing, Apixaban did not achieve a bright performance However, such a huge variety, many domestic players have been stupid, Howson Pharmaceuticals, Zhengda Qing Pharmaceuticals, East Sunshine, Collon Pharmaceuticals .. Involved in imitation Referring to the development of clopidogrel, with the 2022 Apixaban patent expired ringtones, domestic band procurement is estimated to be in distress, the above-mentioned manufacturers Moquan slap to start a new round of price killing Table 4 Domestic apixaban listing in 2019 BMS heavy gold acquisition of the new base company, won multiple myeloma (MM) heavy products - comenadoamine MM is the second largest malignant tumor in the blood system of non-Hodgkin's lymphoma, accounting for about 13% of the malignant tumor of the hematologic system At the same time MM is also an incurable disease, the main goal of clinical treatment is to extend the survival of patients as far as possible, the overall market capacity is huge With sales of $9.685 billion in 2018, it is the world's best-selling cancer drug But with the approval of Johnson and Johnson's Daremu monoto-resing drug, the company also faces a huge challenge, with growth slowing and expected to generate sales of $12.4 billion in 2025 The domestic market, Baiji Shenzhou is responsible for the sale of nado amine, due to the relatively high price, the market has not completely released With the launch of shuangyu pharmaceutical, Zhengda Qing and Qilu pharmaceutical generics, the price of indomine has also begun to fall, from the initial 20,000 or so to 34,000 today Unsurprisingly, two cornerstone drugs for multiple myeloma: indomine and boratizomi, the band purchase has been finalized BTK inhibitor Ibtinib was approved by the FDA on November 13, 2013 for the treatment of multiple lymphomas, called Imbruvica ® Ibutini is expected to sell $11.9 billion in 2025 Because btK small molecular inhibitors are very specific, in B-cell malignancies and some B-cell immunology treatment shows very good advantages, BTK inhibitors have become the best market prospects for hematoma market Over the next four years, Ilutini's annual sales have climbed and it has become a top-tier super-heavyweight bomb, reaching $6.205 billion in 2018 The most exciting thing in this month's circle is that the second-generation BTK inhibitors of Baiji Shenzhou crossed the Pacific Ocean and ascended to the Top of the United States, becoming the first drug to be approved for market by the FDA In addition to the efficacy of cell lymphoma significantly better than ibtinib, but also comes with the "made in china" label, defined the lowest price, for the national eyebrows raised a blow Domestically, Johnson and Johnson's Ibtini in the 2018 health care catalog negotiation process, the price reduction of 80% successfully into the tumor health insurance catalog, with Baiji's Zebbutini listed in the immediate, in a good reputation, the BTK market is imminent In 2018, AbbVie's Adamum Single Fight took $19.9 billion, was approved for 17 indications worldwide and won the crown with a crushed performance There is really a martial arts novel alone to defeat the meaning: whining, life for an enemy and can not get, sincere silence is also embarrassing The drug demon xiu meile is invincible in the world, is the flag in the world But after 2019, sales began to decline as patent protections expired and shocks in the U.S and European markets AbbVie's first-quarter 2019 results showed that Siomer's global sales fell 5.6 percent to $4.446 billion Global expects Adamum's sales to be $10.3 billion in 2025 Unlike the hot foreign market, TNF-alpha inhibitors led by Adamu monotosuppressa in the domestic market performance can be described as unsatisfactory, the leader - Sansheng Guojian occupied half of the TNF-alpha inhibitors, sales in 1 billion yuan, Adamu monoidatal only contributed 200 million, really does not match the title of the global drug king The contrast in the domestic market is ultimately due to the high price of TNF-alpha biologics, with the listing of the first Adamu monoto-remtovictintated in Baio Thailand, a large number of pharmaceutical companies flocked in, Andervie also struggled to begin to comply with "public opinion." Has been everyone "angry" self-exemption market can usher in a big outbreak in the future, biological analogues will enter the next collection list? All make the industry think-ones With Gilead's defeat in the hepatitis C market, the focus of the antiviral market is back on HIV The battle for the HIV market has focused on ace duels between Nofovir amine (Gilead's new nucleoside reverse transcriptase inhibitor - TAF) and Dothravir ( GSK's most relient integrative enzyme inhibitor) In the face of the decline in the market for this major symbol, Truvada, Gilead played the TAF in time, which has a better viral suppression effect and safety than the previously listed Fuma acid in Novovir Biktarvy was highly anticipated by Gilead, and a combination of TAF-based compounds was introduced with an integrated enzyme inhibitor, which was more effective than previous compound drugs In less than a year, it took in $1,184 million, a super-heavy bomb Biktarvy's sales are expected to be $10 billion in 2025 Table 5 Hiv drug TOP10 breast cancer in 2018 is the most common in women, with estrogen (ER) receptors, progesterone receptors (PR) and human epidermal growth factor (HER2) receptors tendto overexpression Estrogen and progesterone receptors are collectively called hormone receptorHR Clinically, breast cancer is divided into four categories based on gene expression and protein levels in tumor tissue (plus positive, -negative): Table 6 Breast cancer type Luminal A, (HR plus/HER2-) breast cancer is the highest incidence of subtype, accounting for 60% Previously, the clinical first-line drug tolordin (which can reduce estrogen levels) median progression survival was only 14.5 months, while CDK4/6-Peapersili combined with the median PFS reached 24.8 months, becoming the most significant breakthrough in breast cancer in recent decades With such a significant therapeutic advantage, the market is rapidly releasing sales of US$4.118 billion in 2018 and expected to generate sales of US$9 billion in 2025, replacing qutodzumab as the number one for breast cancer In the domestic market, Hengrui's CDK4/6 inhibitor-SHR6390 structure is similar to the one that is comparable to the one that is most cost-effective, and only replaces the pyridine on the argon, which is currently in clinical phase III Coupled with last year's listing of HER2 small molecular inhibitor pyrithydal, the domestic breast cancer market is in the future In the psoriasis market, Johnson and Novartis's intersection echoed each other and took a heavy weight IL-12/23 Ustenu Singa, with its leading edge, is currently leading the market for psoriasis, with sales of $5.1 billion in 2018 Table 7 Ussnu sing-sing-sing-sing-Su-Su-Su-King-Su-King-Su-Su-Jin-Su-Trump-based head-to-head research, defeated Ussnu sing-sing-sing-in-the-market, there is a tendency to catch up And Johnson and Johnson did not wait to die, 2017 listed IL-23 single anti-guselkumab in the following year with Sujin single anti-head-to-head research PK success before the snow shame, can be called love and kill With the launch of several heavy-weight drugs in the psoriasis market, the growth rate of ussnozumab is slowing, with sales expected to be $7.5 billion in 2025 Diabetes market, insulin with a number of explosive drug patents expired, other kinds of competition, the market worries about external problems, began to decline in the share In 2018 Novo Nordisk's GLP-1 inhibitor liraglutide has taken over Sanofi's insulin glargine and become the dominant diabetes player GlP-1 receptor agonists have the advantage of lowering blood sugar with additional cardiovascular benefits, reduce food intake and delay gastric emptying, help control weight (weight-loss drugs), and become the hottest area of the diabetes market Table 8 The diabetes market TOP10 Lilly's do-laced glucan is even more unsuccessful, maintaining rapid growth each year, contributing $3.2 billion in 2018 and expected to replace Liraglutide's king in two years, with sales expected to be $7.2 billion by 2025 Of course, Novo Nordisk, the king of diabetes, will certainly not hand over the throne to Lilly The "head-to-head" of sugar-lowering and weight-loss effects, launched in December 2017, became the best diabetes drug of all time Somarutide had sales of $466 million in the third quarter of 2019 and $1.026 billion in the first three quarters, with full-year sales expected to be $1.6-2 billion In addition, in September 2019, the oral version of Somarutide was also approved by the FDA for the market, the mountain rain to come, a battle for the king of diabetes quietly staged In the domestic market, Howson has listed the first long-acting GLP-1 drug - Lothian peptides, with GLP-1 drug price reduction into the health care catalog, the importance of domestic guidance, the market gradually began to release According to Novo Nordisk, the share of GLP-1 in China's diabetes market rose to 1.9% in 2019 from 1.2% last year Originally published as 2025's list of the world's best-selling drugs: A comeback